Raymond James & Associates grew its holdings in shares of ImmunoGen, Inc. (NASDAQ:IMGN) by 3.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 648,758 shares of the biotechnology company’s stock after acquiring an additional 23,459 shares during the quarter. Raymond James & Associates owned about 0.44% of ImmunoGen worth $6,312,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of the company. Xact Kapitalforvaltning AB boosted its position in shares of ImmunoGen by 29.6% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 24,100 shares of the biotechnology company’s stock valued at $234,000 after acquiring an additional 5,500 shares during the last quarter. Amalgamated Bank raised its holdings in shares of ImmunoGen by 46.3% during the 2nd quarter. Amalgamated Bank now owns 19,529 shares of the biotechnology company’s stock valued at $190,000 after buying an additional 6,183 shares in the last quarter. Great West Life Assurance Co. Can raised its holdings in shares of ImmunoGen by 75.1% during the 2nd quarter. Great West Life Assurance Co. Can now owns 15,767 shares of the biotechnology company’s stock valued at $153,000 after buying an additional 6,763 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of ImmunoGen by 1.6% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 531,076 shares of the biotechnology company’s stock valued at $5,587,000 after buying an additional 8,112 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of ImmunoGen by 13.6% during the 1st quarter. Principal Financial Group Inc. now owns 87,202 shares of the biotechnology company’s stock valued at $918,000 after buying an additional 10,440 shares in the last quarter. Hedge funds and other institutional investors own 83.76% of the company’s stock.
Shares of NASDAQ IMGN opened at $9.40 on Thursday. The stock has a market cap of $1.38 billion, a P/E ratio of -12.53 and a beta of 1.95. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.73 and a current ratio of 5.76. ImmunoGen, Inc. has a 1-year low of $4.80 and a 1-year high of $13.41.
A number of equities analysts recently weighed in on the company. HC Wainwright set a $18.00 price objective on ImmunoGen and gave the company a “buy” rating in a report on Tuesday, June 5th. BidaskClub raised ImmunoGen from a “strong sell” rating to a “sell” rating in a report on Tuesday, August 14th. ValuEngine raised ImmunoGen from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 2nd. Finally, Zacks Investment Research cut ImmunoGen from a “hold” rating to a “sell” rating in a report on Thursday, August 2nd. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $12.42.
In other ImmunoGen news, VP Anna Berkenblit sold 5,851 shares of ImmunoGen stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $9.46, for a total value of $55,350.46. Following the transaction, the vice president now directly owns 138,620 shares of the company’s stock, valued at approximately $1,311,345.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.44% of the stock is owned by insiders.
ImmunoGen Company Profile
ImmunoGen, Inc, a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL.
Want to see what other hedge funds are holding IMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ImmunoGen, Inc. (NASDAQ:IMGN).
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.